Delivery Order SPE2DB25D3201-SPE2DB25FNVGF
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 12, 2025, by the Defense Logistics Agency (DLA) for the supply of Eliquis 2.5 mg tablets in a 60-count package configuration. This firm fixed-price delivery order carries a ceiling value of $3,931.20 and is scheduled for completion by September 15, 2025. The award was made through open competition with no set-aside designation and represents a...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a firm fixed-price delivery order valued at $95,223.63 by the Defense Logistics Agency (DLA) for the supply of Eliquis 5 mg tablets (60-count units). The contract, awarded August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-competitive, open-market award. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) on August 13, 2025, for Eliquis 5 mg tablets in a 60-count package. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $10,815.81 and is set to be completed by August 14, 2025. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,157.96 by the Defense Logistics Agency (DLA) on July 28, 2025, with an ultimate completion date of July 29, 2025. The award is for the supply of Eliquis 5 mg tablets in a 60-count quantity, representing a firm fixed price, competitively awarded delivery order with no set-aside designation. This contract award is executed as a child order under...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $12,756.45 by the Defense Logistics Agency on September 4, 2025, for the supply of Eliquis 5 mg tablets (60-count units). The contract is classified as a non-set-aside award with firm fixed-price terms and an ultimate completion date of September 5, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $25,897.33. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Eliquis 5 mg tablets (60-count) with a ceiling value of $5,382.14. This is a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a $17,176.10 delivery order from the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Eliquis 5 mg tablets (60-count). This firm fixed-price, competitively awarded contract represents a child award under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order carries no set-aside...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order by the Defense Logistics Agency on July 24, 2025, for 60 tablets of Eliquis 2.5 mg with a ceiling value of $1,989.38. This non-competitive delivery order is set to be completed by July 25, 2025, and represents a pharmaceutical supply requisition under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract award supports the Defense...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $8,156.88 by the Defense Logistics Agency Medical Supply Chain on July 25, 2025, for the supply of Eliquis 5 mg tablets (60-count). The contract represents a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and is being performed at the contractor's corporate office in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation and is a child contract...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB25FNVGFDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $31,698.09 by the Defense Logistics Agency on July 31, 2025, for the supply of Eliquis 5 mg tablets (60-count). The award utilizes a firm fixed-price contract structure with an ultimate completion date of August 1, 2025, and carries no set-aside designation, indicating it was awarded through open competition. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The Eliquis delivery supports the Defense Health Agency's pharmaceutical supply chain requirements for military and veteran healthcare systems. As a prime vendor under the DLA Troop Support Medical program, AmerisourceBergen maintains a comprehensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's role as a critical pharmaceutical vendor enables it to fulfill federal procurement needs for anticoagulation therapy and other essential medications supporting military healthcare operations globally. The contract reflects the company's established capability to meet federal medical procurement standards through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.7k | 7/31/25 |